Inosita Plus 50/850mg Tablets – Sitagliptin+Metformin HCl

Brand Name: Inosita Plus

Generic Name: Sitagliptin + Metformin HCl

Dosage Strength: 50mg Sitagliptin + 850mg Metformin HCl

Manufacturer: PharmaEvo Pharmaceutical (Pvt) Ltd.

Packing: 28 Tablets

Description and Usage:

Inosita Plus (Sitagliptin+Metformin HCl) 50/850mg Tablets are indicated for the management of type 2 diabetes mellitus in adults. This combination medication helps to control blood sugar levels by multiple mechanisms of action.

Sitagliptin: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the enzyme DPP-4, which in turn increases the levels of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin release from pancreatic beta cells and decrease glucagon secretion from pancreatic alpha cells, thereby reducing blood glucose levels.
Metformin Hydrochloride: Metformin is a biguanide medication that works primarily by decreasing hepatic glucose production and increasing peripheral glucose uptake and utilization. It also improves insulin sensitivity in peripheral tissues such as muscle and adipose tissue.

Category: Diabetes Drugs

Description
Reviews (0)

Description

The realm of diabetes management continues to witness innovative strides, and the introduction of combination therapies represents a significant milestone in this journey.

Among these advancements is Inosita Plus 50/850mg Tablets, a formulation that synergizes the therapeutic effects of Sitagliptin and Metformin Hydrochloride (HCl).

Let’s explore the intricacies of this medication and its potential impact on type 2 diabetes management.

Understanding Type 2 Diabetes:

Type 2 diabetes, a prevalent chronic condition, stems from insulin resistance and inadequate insulin production.

Uncontrolled, it poses severe health risks.

Thus, effective management is imperative.

The Dynamic Duo: Sitagliptin and Metformin HCl:

Sitagliptin:

Belonging to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, Sitagliptin enhances incretin hormones, regulating insulin and glucagon secretion, fostering glycemic control.

Metformin HCl:

A cornerstone in diabetes therapy, Metformin HCl mitigates hepatic glucose output, enhances insulin sensitivity, and slows intestinal glucose absorption.

The Synergy Unleashed:

Combining Sitagliptin and Metformin HCl in Inosita Plus tablets unleashes a potent synergy:

Comprehensive Glycemic Control:

Addressing multiple facets of glucose regulation yields more comprehensive glycemic management.

Side Effect Mitigation:

The blend may allow for lower individual doses, potentially minimizing adverse effects while maximizing therapeutic benefits.

Enhanced Adherence:

Streamlining treatment into a single tablet enhances patient adherence, crucial for long-term diabetes management success.

Dosage and Considerations:

Inosita Plus 50/850mg Tablets typically contain 50mg of Sitagliptin and 850mg of Metformin HCl.

Dosage adjustments may be necessary based on individual needs and medical history, necessitating professional guidance.

Safety and Precautions:

While generally well-tolerated, potential side effects include gastrointestinal disturbances and, rarely, lactic acidosis.

Patients with renal or hepatic impairment require cautious monitoring.

Conclusion:

Inosita Plus 50/850mg Tablets embody a significant advancement in type 2 diabetes management, amalgamating Sitagliptin and Metformin HCl for intensified efficacy and convenience.

However, prudent usage under medical supervision remains paramount for optimal outcomes.

Buy: Arbi 150mg Tablets – Irbesartan

Reviews

There are no reviews yet.

Be the first to review “Inosita Plus 50/850mg Tablets – Sitagliptin+Metformin HCl”